Chris Moore’s Post

In your opinion, who are the top experts (academics and/or practicing physicians) in Inflammatory Bowel Disease (IBD) the pharmaceutical companies follow and trust? Please share your opinions - we want to compare human suggestions with the findings of our AI

Thoughts on this? >> Adcomm says Intercept's rare liver disease drug should not get full approval >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #biotech #healthcare

Drug-Coated Balloon for In-Stent Restenosis Treatment by Boston Scientific Gets from FDA Green Light Boston Scientific has received FDA approval for its drug-coated balloon to treat in-stent restenosis, a condition where a stented artery narrows again due to plaque buildup or scar tissue. This approval is significant because coronary artery disease (CAD) remains a leading cause of death worldwide, and current treatment options for in-stent restenosis have limitations. The Agent balloon, coated with paclitaxel, demonstrated effectiveness in a study and is expected to become a significant player in the global market, potentially worth $500 million. The approval marks a significant advancement in treating in-stent restenosis and offers new hope for patients. For more details please click the link! https://lnkd.in/dARU6_p4 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Crohn’s Disease Treatment Enhanced: FDA Approves Subcutaneous Form of Takeda’s Entyvio The US FDA has approved Takeda Pharmaceuticals' subcutaneous (SC) formulation of Entyvio as a maintenance therapy for adults with moderately to severely active Crohn's disease. The approval was based on data from the Phase III VISIBLE 2 trial, which showed that 48% of patients who received Entyvio injections achieved clinical remission. This highlights the efficacy of the SC formulation in managing Crohn's disease. The FDA had previously approved the SC version of Entyvio for ulcerative colitis. Takeda aims to provide treatment options that help patients achieve remission while offering flexibility in administration methods. For more details please click the link! https://lnkd.in/dW_kSTid #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Proudly sharing this interesting case study we did on how Ovid is used to maximize research productivity for the development of rare disease treatments. Give it a read ↓ Learn how a global pharmaceutical company leveraged Ovid® medical research solutions’ precision and speed to maximize search productivity and improve organizational workflow. Read the case study: https://gag.gl/uUptWs #pharma #medicalresearch

Thoughts on this? >> FDA is poised to pull Ocaliva as adcomm documents question post-approval study results >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #productmarketing #pharmaceutical

Thoughts on this? >> FDA is poised to pull Ocaliva as adcomm documents question post-approval study results >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare

Thoughts on this? >> Adcomm says Intercept's rare liver disease drug should not get full approval >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare

Product-specific guidelines for bioequivalence are essential for developing safe and effective generic products. They guide manufacturers in demonstrating therapeutic equivalence to reference drugs, streamlining regulatory approval and instilling confidence in generic drug interchangeability. Regulatory authorities, such as the US FDA and EMA, make these guidelines easily accessible through searchable databases, serving as a centralized platform for manufacturers amidst the dynamic and constantly evolving landscape of generic product regulations. Read on to know more https://lnkd.in/gMj6JBKW Reach out to DDReg for end-to-end regulatory support for generic product development and approval. Email us at [email protected] or submit your query here https://lnkd.in/dky_SKD7 #regulatoryservices #generic #pharma #FDA #EMA #guidelines #database #bioequivalence

Learn more about the transformation happening in the pharmaceutical industry for the treatment of rare diseases.